Nov 13, 2026 7:45 am EST TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Nov 4, 2026 9:15 am EST TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
Oct 26, 2026 7:30 am EDT TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
Oct 13, 2026 7:45 am EDT TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
Oct 5, 2026 7:45 am EDT TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
Sep 14, 2026 7:45 am EDT TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
Sep 8, 2026 7:45 am EDT TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Aug 14, 2026 7:45 am EDT TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Jul 22, 2026 7:40 am EDT TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
Jun 15, 2026 7:45 am EDT TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers